Literature DB >> 15780061

Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis.

P Deltenre1, P Mathurin, S Dharancy, R Moreau, P Bulois, J Henrion, F R Pruvot, O Ernst, J C Paris, D Lebrec.   

Abstract

UNLABELLED: Transjugular intrahepatic portosystemic shunt (TIPS) is a more effective treatment for refractory ascites than large volume paracentesis (LVP), but the magnitude of its effect in terms of control of ascites, encephalopathy and survival has not been established. AIM: This meta-analysis compare TIPS to LVP in terms of control of ascites at 4 and 12 months, encephalopathy and survival at 1 and 2 years.
RESULTS: Five randomized controlled trials involving 330 patients were included. In the TIPS group, control of ascites was more frequently achieved at 4 months (66% vs 23.8%, mean difference: 41.4%, 95% confidence interval (CI): 29.5-53.2%, P < 0.001) and 12 months (54.8% vs 18.9%, mean difference: 35%, 95% CI: 24.9-45.1%, P < 0.001), whereas encephalopathy was higher (54.9% vs 38.1%, mean difference: 17%, 95% CI: 7.3-26.6%, P < 0.001). Survival at 1 year (61.7% vs 56.5%, mean difference: 3.2%, 95% CI: -14.7 to 21.9%) and 2 years (50% vs 42.8%, mean difference: 6.8%, 95% CI: -10 to 23.6%) were not significantly different.
CONCLUSIONS: TIPS is a more effective treatment for refractory ascites than LVP. However, TIPS increase encephalopathy and does not improve survival. Copyright Blackwell Munksgaard 2005

Entities:  

Mesh:

Year:  2005        PMID: 15780061     DOI: 10.1111/j.1478-3231.2005.01095.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  36 in total

1.  Treatment of refractory ascites.

Authors:  Praveena G Velamati; H Franklin Herlong
Journal:  Curr Treat Options Gastroenterol       Date:  2006

Review 2.  Cardiovascular determinants of survival in cirrhosis.

Authors:  Samuel S Lee; Hongqun Liu
Journal:  Gut       Date:  2007-06       Impact factor: 23.059

3.  Ascites in patients with cirrhosis.

Authors:  Giulia-Anna Perri
Journal:  Can Fam Physician       Date:  2013-12       Impact factor: 3.275

Review 4.  What's new in the treatment of ascites and spontaneous bacterial peritonitis.

Authors:  Andrés Cárdenas; Pere Ginès
Journal:  Curr Gastroenterol Rep       Date:  2008-02

5.  Transjugular intrahepatic portosystemic shunt in the management of refractory ascites.

Authors:  Guadalupe Garcia-Tsao
Journal:  Semin Intervent Radiol       Date:  2005-12       Impact factor: 1.513

6.  Hepatic encephalopathy: you should only comment on what you have actually measured.

Authors:  Sara Montagnese; Sami Schiff; Angelo Gatta; Oliviero Riggio; Marsha Y Morgan; Piero Amodio
Journal:  J Gastroenterol       Date:  2009-12-10       Impact factor: 7.527

Review 7.  Selection of a TIPS stent for management of portal hypertension in liver cirrhosis: an evidence-based review.

Authors:  Xing-Shun Qi; Ming Bai; Zhi-Ping Yang; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

Review 8.  Evidence-based clinical practice guidelines for liver cirrhosis 2015.

Authors:  Hiroshi Fukui; Hidetsugu Saito; Yoshiyuki Ueno; Hirofumi Uto; Katsutoshi Obara; Isao Sakaida; Akitaka Shibuya; Masataka Seike; Sumiko Nagoshi; Makoto Segawa; Hirohito Tsubouchi; Hisataka Moriwaki; Akinobu Kato; Etsuko Hashimoto; Kojiro Michitaka; Toshikazu Murawaki; Kentaro Sugano; Mamoru Watanabe; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2016-05-31       Impact factor: 7.527

Review 9.  Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications.

Authors:  Sith Siramolpiwat
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

10.  Survival and variceal rehemorrhage after shunting support small-diameter prosthetic H-graft portacaval shunt.

Authors:  Alexander Rosemurgy; Donald Thometz; Whalen Clark; Desiree Villadolid; Elizabeth Carey; Daphne Pinkas; Steven Rakita; Emmanuel Zervos
Journal:  J Gastrointest Surg       Date:  2007-03       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.